immunocore.com (IMCR): Utang marang Ekuitas

Logo korporat perusahaan Immunocore Corp (IMCR)

A bet on a unique staff of leading T-cell researchers provides Immunocore Holdings plc (IMCR) with resilience, as confirmed by the history of changes in the total debt-to-equity ratio. The 1.09 level reflects the current magnitude of leverage. Financial stability is based on innovation centers and partnerships with pharma behemoths, while a market advantage is created through an exclusive TCR platform for solid tumor therapy.

IMCR: Rasio Total Utang marang Ekuitas Immunocore 04.07.2022 - 01.11.2026

Rincian metrik komprehensif lan analitis Immunocore Corp (IMCR)

- rega lan prakiraan konsensus rega:
Bagan rega Immunocore|IMCR - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Immunocore|IMCR - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Immunocore|IMCR - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku immunocore.com|IMCR - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Immunocore Holdings plc|IMCR - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Immunocore Holdings plc|IMCR - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Immunocore|IMCR - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Immunocore|Indikator likuiditas cepet immunocore.com
- informasi bathi lan kelipatan valuasi:
IMCR - Bathi pungkasan
Analisis fundamental perusahaan:Immunocore, IMCR
Barang utama Immunocore Holdings plc

Asset stress testing begins with an analysis of capital structure stability. Immunocore Holdings plc (IMCR) develops innovative cancer treatment methods through partnerships with global pharma behemoths. This metric measures the proportion of borrowed funds relative to equity, reflecting the level of debt load. By analyzing the financial leverage chart for Immunocore Holdings plc (IMCR), an investor determines the business's dependence on external creditors. A low ratio confirms financial autonomy when implementing costly clinical trials.

Pesaing Immunocore Holdings plc (IMCR)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Janux Therapeutics Inc JANX|Utang marang Ekuitas Arcus Bio (RCUS)|Zymeworks Biopharmaceuticals - Rasio Utang marang Ekuitas|Total Utang marang Modal TNGX (Tango Therapeutics)|IOVA - Rasio Total Utang marang Ekuitas|IMTX - Utang marang Ekuitas|Utang marang Modal Xencor Inc|Compass Bio (CMPX) - Utang marang Ekuitas|REPL (Replimune Inc.) - Utang marang Ekuitas|Utang marang Ekuitas Lyell Immunopharma|Utang marang Modal innate-pharma.com IPHA|Total Utang marang Modal PYXS|cgen.com (CGEN) - Rasio Utang marang Modal|IO Biotech Corp - Rasio Total Utang marang Ekuitas|Sutro Biopharma, Inc (STRO) - Utang marang Modal|INKT: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi HOWL (Werewolf Therapeutics)|IMMX: Total Utang marang Modal|ALXO - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cue Biopharma, Inc.|Rasio Total Utang marang Ekuitas PDS Biotechnology Corp (PDSB)|Utang marang Ekuitas Sonnet BioTherapeutics (SONN)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal